LifeStance Health Group, Inc. (NASDAQ:LFST) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of LifeStance Health Group, Inc. (NASDAQ:LFST) have been given an average recommendation of “Moderate Buy” by the nine analysts that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, five have given a buy rating and two have issued a strong buy rating on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $8.8333.

LFST has been the subject of several recent research reports. Barclays assumed coverage on LifeStance Health Group in a research report on Tuesday, December 9th. They set an “overweight” rating and a $8.00 price target for the company. Wall Street Zen upgraded LifeStance Health Group from a “hold” rating to a “buy” rating in a research report on Friday, January 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of LifeStance Health Group in a research note on Monday, December 29th. UBS Group raised their price target on shares of LifeStance Health Group from $9.00 to $10.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. Finally, BTIG Research boosted their price objective on shares of LifeStance Health Group from $9.00 to $10.00 and gave the company a “buy” rating in a research report on Friday, December 12th.

Insiders Place Their Bets

In other LifeStance Health Group news, Director Robert Bessler sold 119,942 shares of the stock in a transaction on Friday, December 19th. The stock was sold at an average price of $7.04, for a total transaction of $844,391.68. Following the transaction, the director owned 1,318,983 shares of the company’s stock, valued at $9,285,640.32. This represents a 8.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Ann Varanakis sold 50,000 shares of LifeStance Health Group stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $6.90, for a total value of $345,000.00. Following the completion of the sale, the insider directly owned 315,610 shares of the company’s stock, valued at approximately $2,177,709. This represents a 13.68% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 327,326 shares of company stock valued at $2,259,317 in the last quarter. 6.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of LFST. Park Edge Advisors LLC boosted its holdings in LifeStance Health Group by 14.4% in the 4th quarter. Park Edge Advisors LLC now owns 11,863 shares of the company’s stock worth $84,000 after acquiring an additional 1,495 shares during the period. Vident Advisory LLC raised its stake in shares of LifeStance Health Group by 12.7% during the second quarter. Vident Advisory LLC now owns 21,732 shares of the company’s stock valued at $112,000 after purchasing an additional 2,447 shares during the period. State of Wyoming lifted its position in shares of LifeStance Health Group by 3.8% during the third quarter. State of Wyoming now owns 89,927 shares of the company’s stock worth $495,000 after purchasing an additional 3,298 shares in the last quarter. Legal & General Group Plc boosted its stake in shares of LifeStance Health Group by 2.4% in the second quarter. Legal & General Group Plc now owns 144,263 shares of the company’s stock valued at $746,000 after purchasing an additional 3,331 shares during the period. Finally, Polar Capital Holdings Plc boosted its stake in shares of LifeStance Health Group by 19.3% in the third quarter. Polar Capital Holdings Plc now owns 21,775 shares of the company’s stock valued at $120,000 after purchasing an additional 3,525 shares during the period. Institutional investors and hedge funds own 85.50% of the company’s stock.

LifeStance Health Group Stock Performance

Shares of LFST opened at $7.10 on Wednesday. LifeStance Health Group has a 12-month low of $3.74 and a 12-month high of $8.30. The stock has a market cap of $2.76 billion, a P/E ratio of -236.67 and a beta of 1.12. The company has a current ratio of 1.58, a quick ratio of 1.58 and a debt-to-equity ratio of 0.18. The company has a 50-day moving average of $6.92 and a two-hundred day moving average of $5.77.

LifeStance Health Group (NASDAQ:LFST) last released its quarterly earnings results on Wednesday, November 5th. The company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.03. LifeStance Health Group had a negative net margin of 0.67% and a negative return on equity of 0.62%. The business had revenue of $363.81 million for the quarter, compared to analyst estimates of $355.06 million. During the same period in the prior year, the business earned ($0.02) earnings per share. The company’s quarterly revenue was up 16.3% on a year-over-year basis. As a group, research analysts predict that LifeStance Health Group will post -0.18 EPS for the current fiscal year.

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.